6 days Ago By ABMN Staff
Legal & General Group Plc lessened its stake in Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI – Free Report ) by 11.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC.
The fund owned 122,393 shares of the company’s stock after selling 16,553 shares during the quarter. Legal & General Group Plc’s holdings in Maravai LifeSciences were worth $667,000 at the end of the most recent reporting period. A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock.
Barclays PLC raised its holdings in shares of Maravai LifeSciences by 349.2% during the 3rd quarter. Barclays PLC now owns 184,189 shares of the company’s stock worth $1,531,000 after acquiring an additional 143,184 shares during the period.
Franklin Resources Inc. purchased a new stake in shares of Maravai LifeSciences in the 3rd quarter valued at approximately $600,000. JPMorgan Chase & Co.
increased its holdings in shares of Maravai LifeSciences by 1,172.4% during the 3rd quarter. JPMorgan Chase & Co.
now owns 4,050,245 shares of the company’s stock worth $33,658,000 after buying an additional 3,731,924 shares during the last quarter. FNY Investment Advisers LLC raised its position in shares of Maravai LifeSciences by 600.0% during the 4th quarter.
FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock valued at $38,000 after buying an additional 6,000 shares during the period. Finally, SG Americas Securities LLC lifted its holdings in Maravai LifeSciences by 7.3% in the fourth quarter.
SG Americas Securities LLC now owns 33,046 shares of the company’s stock valued at $180,000 after acquiring an additional 2,239 shares during the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.
Analyst Upgrades and Downgrades A number of research firms have commented on MRVI. Bank of America reduced their target price on Maravai LifeSciences from $9.00 to $8.
00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. UBS Group decreased their target price on shares of Maravai LifeSciences from $8.00 to $2.
50 and set a “neutral” rating on the stock in a research report on Friday, March 21st. Robert W. Baird downgraded shares of Maravai LifeSciences from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $9.
00 to $3.00 in a research note on Wednesday, February 26th. Morgan Stanley lowered their price objective on shares of Maravai LifeSciences from $7.
00 to $5.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 25th. Finally, Baird R W cut Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th.
One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Maravai LifeSciences presently has an average rating of “Hold” and an average price target of $6.34.
Insider Transactions at Maravai LifeSciences In related news, General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $5.03, for a total value of $125,750.
00. Following the transaction, the general counsel now directly owns 167,618 shares of the company’s stock, valued at $843,118.54.
This trade represents a 12.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website .
Corporate insiders own 0.63% of the company’s stock. Maravai LifeSciences Stock Performance Shares of Maravai LifeSciences stock opened at $2.
01 on Tuesday. Maravai LifeSciences Holdings, Inc. has a one year low of $1.
67 and a one year high of $11.56. The business has a 50-day simple moving average of $2.
41 and a 200-day simple moving average of $4.56. The company has a debt-to-equity ratio of 0.
89, a quick ratio of 9.94 and a current ratio of 10.74.
The company has a market cap of $511.22 million, a PE ratio of -1.23 and a beta of 0.
18. About Maravai LifeSciences ( Free Report ) Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Articles Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI – Free Report ).
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter ..
